Pharmaceutical care: Past, present and future

Current Pharmaceutical Design

Volumn 10, Issue 31, 2004, Pages 3931-3946

  Berenguer, B ^a   La Casa, C ^a   de la Matta, M J ^a   Martin Calero M J ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; AWARENESS; BIOMEDICINE; CHRONIC PAIN; CLINICAL PRACTICE; COMMERCIAL PHENOMENA; DIABETES MELLITUS; DRUG UTILIZATION; ECONOMIC ASPECT; EUROPE; GOOD CLINICAL PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL DISEASE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RESPONSIBILITY; REVIEW; RHEUMATIC DISEASE; SKILL; SOUTH AND CENTRAL AMERICA; TREATMENT FAILURE; UNITED STATES;

FORECASTING; HUMANS; INTERNATIONALITY; PHARMACEUTICAL SERVICES; SOCIETIES, PHARMACEUTICAL;

EID: 9944235758     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382521     Document Type: Review

References (159)

1. van Mil JWF. Pharmaceutical Care in community pharmacy in Europe, challenges and barriers. Pharm Care Esp 2000; 2: 42-56.
2. Hepler CD. Pharmaceutical care. Pharm World Sci 1996; 18: 233-6.
3. Posey LM. Proving that pharmaceutical care makes a difference in community pharmacy. J Am Pharm Assoc 2003; 43: 136-8.
4. Vuckovic N, Nichter M. Changing patterns of pharmaceutical practice in the United States. Soc Sci Med 1997; 44: 1285-302.
5. Strand LM, Cipolle RJ, Morley PC, Perrier DG. Levels of pharmaceutical care. Am J Hosp Pharm 1991; 48: 547-50.
6. Herrera Carranza J. Objetivos de la atención farmacéutica. Aten Primaria 2002; 30: 183-7.
7. Etemad LR, Hay JW. Cost-effectiveness analysis of Pharmaceutical Care in a Medicare drug benefit program. Value in Health 2003; 6: 425-35.
8. Hatoum HT, Akhras K. Bibliography: a 32-year literature review on the value and acceptance of ambulatory care provided by pharmacists.Ann Pharmacother 1993; 27:1106-19.
9. Hepler CD. Unresolved issues in the future of pharmacy. Am J Hosp Pharm 1988; 45: 1071-1081.
10. Garcao JA, Cabrita J. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm, Assoc 2002; 42: 858-64.
11. Segal R. Applying the principles of pharmaceutical care to the patient with diabetes. Pharm Pract Manag Q 1997; 47: 117-21.
12. Cranor CW, Bunting BA, Christensen DB. The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003; 43: 173-84.
13. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000; 40: 157-65.
14. Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA 2002; 288: 1594-602.
15. Alvarez de Toledo F, Arcos González P, Eyaralar Riera T, Abal Ferrer FF, Dago Martínez A, Cabiedes Miragaya L, et al. Pharmaceutical care in people who have had acute coronary episodes ((TOMCOR study). Rev Esp Salud Pública 2001; 75: 375-87.
16. Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E, et al. Pharmaceutical care of the Elderly in Europe Research (PEER) Group. Improving the well-being of elderly patients via community pharmacy-based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18: 63-77.
17. U.S. Bureau of Health Professions. Report on health professional accessibility. Washington, DC: Government Printing Office; 1996.
18. Garrett DG, Martin LA. The Asheville project: participant's perceptions of factors contributing to the success of a patient self-management diabetes program. J Am Pharm Assoc 2003; 43: 185-90.
19. Del Fiol G, Rocha BH, Nohama P. Design, implementation and evaluation of a clinical decision support system to prevent adverse drug events. Stud Health Technol Inform 2000; 77: 740-4.
20. Ives TJ, Bentz EJ, Gwyther RE. Drug-related admissions to a family medicine inpatient service. Arch Intern Med 1987; 147: 1117-20.
21. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228: 83-90.
22. Rupp MT, DeYoung M, Schondelmeyer SW. Prescribing problems and pharmacist interventions in community practice. Med Care 1992; 30: 926-40.
23. Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann Pharmacother 1992; 26: 1580-4.
24. Redwood H. Pharmaceutical cost containment and quality care. Conflict or compromise? Pharmacoeconomics 1998; 14 Suppl 1: 9-13.
25. Hepler CD. The third wave in pharmaceutical education: the clinical movement. Am H Pharm educ 1987; 51: 369-85.
26. Al-Shaqha WMS, Zairi M. Pharmaceutical care management: a modern approach to providing seamless and integrated health care. Inter J Health Care Qual Assur 2001; 14: 282-301.
27. Control of the Practice of Pharmacy. In: Smith MC, Knapp DA, eds. Pharmacy, drugs and medical care. 4th ed. Baltimore, MD: Williams and Wilkins, 1987; 226-7.
28. Angaram DM, Hepler CD, Bjornson DC, Hadsall RS. Career patterns of pioneer clinical pharmacists. Am J Hosp Pharm 1988; 45: 101-8.
29. Brodie DC. Drug use control: keystone to pharmaceutical service. Drug Intell Clin Pharm 1967; 1: 63-5.
30. Crawford SY, Myers CE. ASP national survey of hospital-based pharmaceutical services. Am J Hosp Pharm 1992; 50: 1371-404.
31. Santell JP. ASHP national survey of hospital-based pharmaceutical services. Am J Hosp Pharm 1994; 52: 1179-98.
32. Oleg BG, McLean WM, Poston JW. The clinical pharmacy services study: a study of clinical services provided by pharmacists in Ontario hospitals. Canad J Hosp Pharm 1996; 49: S5-S25.
33. Reeder C, Dickson M, Kozma C. ASHP national survey of pharmacy practice in acute care settings. Am J Health Syst Pharm 1996; 54: 653-69.
34. Millis JS, et al. Pharmacists for the future: the report of the Study Commission on Pharmacy. Ann Arbor: Health Administration Press 1975.
35. Brodie DC. Need for a theroretical base for pharmacy practice. Harvey AK Whithney Award lectures: 1950-1992. 260-269. Bethesda. American Society of Hospital Pharmacies 1980.
36. Pharmacy in the 21th Century. Alexandria, Va: American Association of Colleges of Pharmacy; 1984
37. Hepler CD. Pharmacy as a clinical profession. Am J Hosp Pharm 1985; 42: 1298-306.
38. Strand LM, Cipolle RJ, Morley PC. Documenting the clinical pharmacist's activities: back to basics. Drug Intell Clin Pharm 1988; 22: 63-7.
39. Hepler CD and Strand LM. Opportunities and responsabilities in Pharmaceutical Care. American Journal of pharmaceutical education 1989; 53: 7s-15s.
40. Hepler CD and Strand LM. Opportunities and responsibilities in Pharmaceutical Care. Am J Hosp Pharm 1990; 47: 533-43.
41. Kubitz C. Introduction to Pharmaceutical care. http://www.pharmazie.uni-halle.de/sp/intropharmcare.html (accessed January 04)
42. Americam Association Colleges of Pharmacy. http://www.aacp.org/ (accessed February 2004).
43. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP 1990; 24: 1093-7.
44. Omnibus budget reconciliation Act of 1990 [5 November 1990. Excerpts]. Digest Public Gen Bills 1990; 101 Pt 2: 213, 217-9.
45. Canaday, BR. OBRA '90: A practical guide to effecting Pharmaceutical Care. American Pharmaceutical Association 1994.
46. Schatz R, Belloto RJ Jr, White DB, Bachamann K. Provision of drug information to patients by pharmacists: the impact of the Omnibus Budget Reconciliation Act of 1990 a decade later. Am J Ther 2003; 10: 93-103.
47. Herborg H, Soendergaard B, Froekjaer B, Fonnesbaek L, Jorgensen T, Hepler CD, et al. Improving drug therapy for patients with asthma-part 1: patient outcomes. J Am Pharm Assoc 2001; 41: 514-50.
48. Pharmaceutical care and its promotion. Consultation Document. The pharmaceutical Journal 1992 December 19/26 pg 802.
49. Tomechko MA, Strand LM, Morley PC, Cipolle RJ. Q and A from the pharmaceutical care project in Minnesota. Am Pharm 1995; NS35: 30-9.
50. Cipolle RJ, Strand LM, Morley PC, Zollo S, Navrozov M Eds, Pharmaceutical care practice. McGraw Hill Health Profession Divisions, The McGraw-Hill Companies, Inc. 1998.
51. Federation of International Pharmacy. http://www.fip.org/ (accessed January 2004).
52. Drugs and medicines policy. World Health Organisation. http://www.who.int/ (accessed January 2004).
53. Pharmaceutical Care Network Europe. http://www.pcne.org/ (accessed January 2004).
54. American Society of Consultant Pharmacists. ASCP Policy Statement. http://www.ascp.com/ (accessed February 2004).
55. Fip Council meeting The Hague 1998. http://www.fip.org/congress/ (accessed February 2004).
56. Holdford D, Kennedy DT, Bernadella P, Small RE. Implementing disease management in community pharmacy practice. Clin Ther 1998; 20: 328-39.
57. Reeder CE, Kozma CM, McCollam AR. Overview of pharmaceutical outcomes, pharmacoeconomics, and quality of life. In: Ito SM, Blackburn SA Eds, Pharmacist's Guide to Principles and Practices of Managed Care Pharmacy. Alexandria, Va, Academy of Managed Care Pharmacy 1995; 103-12.
58. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother 1999; 33: 1336-55.
59. Stergachis A, Gardner JS, Anderson MT, Sullivan SD. Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference? J Am Pharm Assoc 2002; 42: 743-52.
60. Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists' clinical services. Am J Health Syst Pharm 2001; 58: 569-77.
61. Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003; 43: 149-59.
62. Cranor CW, Christensen DB. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003; 43: 160-72.
63. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Pharmacotherapy 2000; 20: 1508-16.
64. Ellis SL, Billups SJ, Malone DC, Carter BL, Covey D, Mason B, et al. Types of interventions made by clinical pharmacists in the IMPROVE study. Impact of managed pharmaceutical care resource utilization and outcomes in veterans affairs medical centers. Pharmacotherapy 2000; 20: 429-35.
65. Bluml BM, McKenney JM, Cziraky MJ, Elswick RK Jr. Interin report from project ImPACT: hyperlipidemia. J Am Pharm Assoc 1998; 38: 529-34
66. Carter BL, Chrischilles EA, Scholz D, Hayase N, Bell N. Extent of services provided by pharmacists in the Iowa Medicaid pharmaceutical case management program. J Am Pharm. Assoc 2003; 43: 24-33.
67. Currie JD, Chrischilles EA, Kuehl AK, Buser RA. Effect of a training program on community pharmacists' detection of and intervention in drug-related problems. J Am Pharm Assoc 1997; NS37: 182-91.
68. Ernst ME, Doucette WR, Dedhiya SD, Osterhaus MC, Kumbera PA, Osterhaus JT, et al. Use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with musculoskeletal disorders. Pharmacotherapy 2001; 21: 988-97.
69. Osterhaus JT, Dedhiya SD, Ernst ME, Osterhaus M, Mehta SS, Towsend RJ. Health outcomes assessment in community pharmacy practices: a feasibility project. Arthritis Rheum 2002; 47: 124-31.
70. Ernst ME, Iyer SS, Doucette WR. Drug-related problems and quality of life in arthritis and low back pain sufferers. Value Health 2003; 6: 51-8.
71. Ryan M, Piascik P. Providing pharmaceutical care to the múltiple sclerosis patient. J Am Pharm Assoc 2002; 42: 753-67.
72. Gammaitoni AR, Gallagher RM, Welz M, Gracely EJ, Knowlton CH, Voltis TO. Palliative pharmaceutical care: A randomized, prospective study of telephone-based prescription and medication counseling services for treating chronic pain. Pain Medicine 2000; 1: 317-31.
73. Turner CJ, Pryse-Phillips W. Pilot study to improve health outcomes for medication-induced headache sufferers. Can J Clin Pharmacol 1999; 6: 113-7.
74. Stoner SC, Worrel JA, Jones MT, Farrar CA, Ramlatchman LV. Pharmacist-designed and implemented pharmaceutical care plan for antipsychotic-induced movement disorders. Pharmacotherapy 2000; 20: 583-8.
75. Sinclair H, Bond C, Stead L. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev 2004; 1: CD003698.
76. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid Dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002; 36. 312-21.
77. Wermeille J, Bennie M, Brown I. Integrating the community pharmacist into the diabetes team: evaluation of a new care model for patients with Type 2 diabetes mellitus. Int J Pharm Pract 2001; 9(suppl): R60.
78. McGovern EM, Mackay C, Hair A, Lindsay H, Bryson SM. Pharmaceutical care needs of patients with angina. Pharm World Sci 2001; 23: 175-6.
79. Bucci C, Jackevicius C, McFarlane K, Liu P. Pharmacist's contribution in a heart function clinic: patient perception and medication appropriateness. Can J Cardiol 2003: 31; 391-6.
80. Nola KM, Gourley DR, Portner TS, Gourley GK, Solomon DK, Elam M, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000; 40: 166-73.
81. Cordina M, McElnay JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy 2001; 21: 1196-203.
82. Herborg H, Soendergaard B, Jorgensen T, Jorgensen T, Fonnesback L, Hepler CD, et al. Improving drug therapy for patients with asthma-part 2: use of anti-asthma medications. J Am Pharma Assoc 2001; 41: 551-9.
83. Bheekie A, Syce JA, Weinberg EG. Peak expiratory rate and symptom self-monitoring of asthma initiated from community pharmacies. J Clin Pharm Ther 2001; 26: 287-96.
84. Manley HJ, Drayer DK, McClaran M, Bender W, Muther RS. Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care in a hemodialysis center. Pharmacotherapy 2003; 23: 231-9.
85. Schulz M, Verheyen F, Muhlig S, et al. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol 2001; 41: 668-76
86. van Mil JWF, Tromp ThFJ, McElnay JC, de Jong-van den LTW. Pharmaceutical care and quality of life of the elderly, the OMA sttudy. Poster presentation at FIP Congress in Vienna 2000.
87. Anderson AC, Brodin H, Nilsson JL. Pharmacy representatives: a non-pharmacy outlet of prescribed medicines in Sweden. Pharm World Sci 2002: 24; 139-43.
88. Sturgess IK, McElnay JC, Hughes CM, Crealey G. Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci 2003; 25: 218-26.
89. Nathan A, Goodyer L, Lovejoy A, Rashid A. 'Brown bag' medication reviews as a meand of optimizing patients use of medication and of identifying potential clinical problems. Farm Pract 1999; 16: 278-82.
90. Chamba G, Bauguil G, Galiezot J. The role of the French community pharmacist in drug dispensing. Pharm World Sci 1999; 21: 142-3
91. Leemans L, Veroeveren L, Bulens J, Hendrickx, et al. Frequency and trends of interventions of prescriptions in Flemish community pharmacies. Pharm World Sci 2003; 25: 65-9.
92. Krska J, Veitch GBA, Calder G. Developing Pharmaceutical Care. The views of the profession. Virtual Poster Gallery. Poster presentation at FIP Congress in Vienna 2000.
93. de Gier JJ. Clinical pharmacy in primary care and community pharmacy. Pharmacotherapy 200; 20: 278-81.
94. Booij AD, de Boer WO, Kokenberg ME, Tromp TF. Interventions in seamless care. Pharm World Sci 2003; 25: 41-2.
95. Holland RV, Nimmo CM. Transitions in pharmacy, part 1: Beyond pharmaceutical care. Am J Health Syst Pharm 1999; 56: 1758-64.
96. Rossing C, Hasen EH, Krass I. The provision of pharmaceutical care in Denmark: a cross-sectional survey. J Clin Pharm Ther 2003; 28:311-8.
97. Rossing C, Hasen EH, Krass I, Traulsen JM. Pharmaceutical care in Denmark: perceived importance of medicine-related problems and participation in postgraduate training. Pharm World Sci 2003; 25: 73-8.
98. Machuca M, Fernández-Llimós F, Faus MJ. Dader Method of Drug-therapy Follow-up. Granada: GIAF; 2003.
99. García Cebrián F, Salar Ibañez L. Programa TOD de la Comunidad de Valencia. Boletín de la Sefac no 4, 2002.
100. Consensus Committee. Second Consensus of Granada on Drug Therapy Problems. Ars Pharmaceutica 2002; 43: 179-187.
101. Paulovic L, Carter N. The role of pharmacists in a pharmaceutical care. Poster presentation at FIP Congress in Nice 2002.
102. Skyrius V Radziunas R, Barsteigiene Z, Baranauskas A, Gricevicius J. Analysis of possibilities of pharmaceutical care elements implementation in Lithuanian community pharmacies. Medicina 2003; 39: 143-7.
103. Dunlop JA, Shaw JP. Community pharmacist' perspectives on pharmaceutical care implementation in New Zealand. Pharm World Sci 2002; 24: 224-30.
104. Shani S, Morginstin T, Hoffman A. Patients' perceptions of drug therapy counselling in Israel. Isr Med Assoc J 2000; 2: 438-41.
105. Critically Examining PC. Sesquicentennial Symposium. JAPA; 2002; 42.
106. Nagai T. Pharmacy, pharmacists and society - pharmaceutical science and practice with philosophy. Yakugaku Zasshi 2003; 123: 143-50.
107. Martínez AM, Lores D, Aguilera E. ¿A qué población vamos a proveer Atención Farmacéutica? Pharm Care Esp 2003; 5: 39-44.
108. Murdaugh C. Health-related quality of life as an outcome in organizational research. Med Care 1997; 35: NS 41-8.
109. Volume CL, Farris KB, Kassam R, Cox CE, Cave A. Pharmaceutical care research and education project: patient outcomes. J Am Pharm Assoc 2001; 41: 411-20.
110. Lida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S, et al. Impact of elevated blood pressure on mortality from all causes, cardiovascular disease, heart disease and stroke among Japanase Nipon data 80. J Hum Hypertens 2003; 17: 851-7.
111. Pickard A, Johnson J, Farris K. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother 1999; 33: 1167-72.
112. Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother 2000; 34: 1320-31.
113. Hanlon JT, Artz M. Drug-related problems and pharmaceutical care: What are they, do they matter, and what's next? Med Care 2001; 39: 109-12.
114. Bernheim JL. How to get serious answers to the serious question: "How have you been" subjective quality of life (QOL) as an individual experiential emergent construct. Bioethics 1999; 13: 272-87.
115. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48: 1978-88.
116. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc 2000; 40: 475-85.
117. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988; 26: 814-23.
118. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630-9.
119. Park JJ, Kelly P, Carter BL, Burgess PP. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996; NS36: 443-51.
120. Kucukarslan S, Schommer JC. Patients' expectations and their satisfaction with pharmacy services. J Am Pharm Assoc 2002; 42: 489-96.
121. Schommer J, Kucukarlan S. Measuring patient satisfaction with pharmaceutical services. Am J Health Syst Pharm 1997; 54: 2721-32.
122. Sitzia J, Wood N. Patient satisfaction: a review of issues and concepts. Soc Sci Med 1997; 45: 1829-43.
123. MacKeigan LD, Larson LN. Development and validation of an instrument to measure patient satisfaction with pharmacy services. Med Care 1989; 27: 522-36.
124. Larson LN, MacKeigan LD. Further validation of an instrument to measure patient satisfaction with pharmacy services. J Pharm Mark Manage 1994; 8: 125-39.
125. Bungay KM. Methods to assess the humanistic outcomes of clinical phamacy services. Pharmacotherapy 2000; 20: 253S-8S.
126. Ried LD, Wang F, Young H, Awiphan R. Patients' satisfaction and their perception of the pharmacist. J Am Pharm Assoc 1999; 39: 835-42.
127. Kamei M, Teshima K, Fukushima N, Nakamura T. Investigation of patients' demand for community phamacies: relationship between pharmacy services and patient satisfaction. Yakugazu Zasshi 2001; 121: 215-20.
128. Gourley GK, Gourley DR, Rigolosi EL, Reed P, Solomon DK, Washington E. Development and validation of the Pharmaceutical Care Satisfaction Questionnaire. Am J Manag Care 2001; 7: 461-6.
129. Larson LN, Rovers JP, MacKeigan LD. Patient satisfaction with pharmaceutical care: Update of a validated instrument. J Am Pharm Assoc 2002; 42: 44-50.
130. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm 1997; 54: 554-8.
131. Schumock GT. Methods to assess the economic outcomes of clinical pharmacy services. Pharmacotherapy 2000; 20: 243S-52S.
132. Plumridge RJ and Wojnar-Horton RE. A review of the pharmaeconomics of pharmaceutical care. Pharmacconomics 1998; 14: 175-89.
133. Dobie RL, Rascatti KL. Documenting the value of pharmacist intervention. Arizona Pharmacist 1994; 75: 8-11.
134. Miller MJ, Ortmeier BG. Factors influencing the delivery of pharmacy services. Am Pharm 1995; NS35: 39-45.
135. Johnson JA, Bootman JL. Drug-related morbility and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-56.
136. McCormack J, Reinhardt G, Hastings, et al. Documented value: Pharmacists who get paid document more. NARD Journal 1996; 18: 39-41.
137. Fincham JE. Pharmaceutical Care studies: A review and update. Drug Benefit Trends 1998; 10: 41-5.
138. Lai LL. Effects of a Pharmaceutical Care intervention in primary ambulatory settings among Medicaid population. Journal of Pharmaceutical Care 1998; 2: article 2. http://rxweb.ulm.edu/pharmacy/JPC/jp10202.htm (accessed February 2004).
139. Poston J, Kennedy R, Waruszynski R. Initial results from the community pharmacist intervention study. Can Pharm J 1995; Dec/Jan: 18-25.
140. Loh EA, Waruszynski MA, Poston J. Cost savings associated with community pharmacist interventions in Canada. Can Pharm J 1996; Feb: 43-52.
141. Benrimoj SI, Langford JH, Berry G, Collins D, Lauchan R, Stewart K, et al. Economic impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance. Pharmacoeconomics 2000; 18: 459-68.
142. Guignard AP, Couray-Targe S, Colin C, Chamba G. Economic impact of pharmacists' interventions with nonsteroidal antiinflammatory drugs. Ann Pharmacother 2003; 37: 332-8.
143. Miller LG, Scott DM. Documenting pharmacist care in rural community pharmacies: How pharmacist care promotes improved drug usage: Final Report. Alexandria, Va., NARD Foundation, 1995
144. Christensen DB, Neil N, Fassett WE, Smith DH, Holmes G, Stergachis A. Frequency and characteristics of cognitive services provides in response to a financial incentive. J Am Pharm Assoc 2000; 40: 609-17.
145. Kroger E, Moisan J, Gregoire JP. Billing for cognitive services: understanding Quebec pharmacists' behavior. Ann Pharmacother 2000; 34: 401-2.
146. Iowa Medicaid Pharmaceutical Case Management Evaluation Plan. J Iowa Pharm Assoc 2000; (Sept/Oct): 15-17.
147. Farris KB, Kumbera P, Halterman T, Fang G. Outcomes-based pharmacist reimbursement: reimbursing pharmacists for cognitive services. J Managed Care Pharm 2002; 5: 383-93.
148. Tranz-Herman N. Information for Pharmaceutical Care. www. zbmed.de/eahil2002/proccedings/trzan-herman-proc.pdf; (accessed February 2004.
149. Cohen JI, Kabat HF, Koda-Kimble MA, Rutledge CO, Smith RE. Are we delivering on our promise to society to assure the safe use of medications? Educating pharmacists to continue adding value to health care. Report of the 2000-2001 Argus Commission. Am J Pharm Educ 2001; 65: 6S-8S.
150. Plaza F. Pharmaceutical Care. Actual state and pharmaceutic service's development: reason for the change. Pharm Care Esp. 1999; 1: 48-51.
151. Faus MJ, Martínez F. Pharmaceutical in community pharmacies: evolution of the concept, training requirements, modalities and implementation strategies. Pharm Care Esp 1999; 1: 52-61.
152. Deselle S, Hunter TS. The evolution of Pharmaceutical care into managed care environments. J Managed Care Pharm 1998; 4:55-58.
153. Glover C. The future of profession. The Pharm J 2000; 264: 13-14.
154. Knapp DA. Pharmacy practice in 2040. Am J Hosp Pharm 1992; 49:2457-61.
155. Barber N. Community pharmacy: alternative visions. The Pharm J 2000; 264: 22-23.
156. Hepler CD. Regulating for outcomes as a systems response to the problem of drug-related morbidity. J Am Pharm Assoc 2001; 41: 108-15.
157. Buchwald UK, Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Design 2003; 9(12): 945-68.
158. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Design 2002; 8(8): 615-57.
159. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Design 2003; 9(2): 175-91.